


## What is known about NMO?

NMO is a rare disorder caused by the immune system attacking the body's healthy cells, with attacks directed mostly against the eyes and the spinal cord

This causes inflammation of the spinal cord and optic nerve, which can cause loss of vision and loss of mobility and sensation.

- Many patients continue to relapse (have attacks) despite treatment
- Disability may get worse with every relapse

Women are more likely to have NMO than men



If you have tested positive for the NMO antibody, you are not alone



Patients who test positive for NMO antibody 75-80%

If you have relapsing NMO, you are not alone



Patients with NMO who will have relapses 90%

## What are we trying to learn about relapsing NMO in this study?

- This research is studying the ability of a medication called eculizumab to prevent relapses in relapsing NMO.
- Eculizumab blocks the immune system's attacks on the body's healthy cells, which may prevent relapses (attacks)
- Eculizumab is not currently approved for the treatment of NMO, but is used as treatment in two other rare diseases in some countries

Eculizumab has been tested previously in a research study of frequently relapsing NMO patients

Previous Study:

 14 patients

During treatment with eculizumab for one year, 12 out of 14 patients were relapse free – 2 patients had possible relapses of back pain and blurred vision

## Risks and side effects

If you participate, it is possible that your NMO symptoms may improve, remain the same or worsen.

Like all medicines, eculizumab can cause side effects, although not everybody will experience them. Your doctor will discuss the possible side effects with you and explain the risks and benefits of eculizumab prior to enrollment. Because eculizumab is being studied in NMO patients, not all possible side effects are known.

## Who is eligible to be part of this study and what are the potential benefits?

You may be eligible to participate if you are an adult, age 18 years or older with:



A confirmed diagnosis of relapsing neuromyelitis optica (NMO) or NMO Spectrum Disorder (NMO-SD)



At least 2 relapses in the last 12 months or  
3 relapses in the last 24 months (with at least 1 relapse in the last 12 months)

If you qualify and decide to participate in this study, you will be assigned to receive either active study drug (eculizumab) or inactive study drug (placebo).

Which treatment you will receive is randomly determined. Randomization is like flipping a coin; you are assigned by chance to either the study drug (eculizumab) or the inactive study drug (placebo).

**2:1** Your chances of receiving eculizumab vs placebo

You may continue to receive your current NMO treatment. Your doctor will discuss this with you.

Patients who complete the study may be eligible to enroll in another separate study, in which all patients receive eculizumab. You should consult with your doctor about participation.

## What are the stages of the study?

- 1. Screening:** Your doctor will determine if you are eligible for the study (1 to 3 weeks).
- 2. Treatment:** You will receive eculizumab or placebo (both by intravenous infusion), every week for the first 5 weeks and then every 2 weeks afterwards. This will last potentially as long as 2 years.
- 3. Relapse or Attack:** If you have a relapse, your doctor will treat you accordingly and you will be monitored for an additional 6 weeks.
- 4. Follow up Period:** Afterwards, you may be eligible to continue in another study—an extension study—where every patient will receive eculizumab.

### 3 reasons to participate

- 1 Access** to a new potential medication for relapsing NMO
- 2 Frequent** medical follow-up
- 3 Advancing** the knowledge of the disease and ways to treat it

Call your doctor to learn more about the study.

For additional information, you can learn more at [clinicaltrials.gov](http://clinicaltrials.gov) or on [AlexionClinicalTrials.com/NMO](http://AlexionClinicalTrials.com/NMO).

Sources:

1. [www.hopkinsmedicine.org/healthlibrary/conditions/nervous\\_system\\_disorders/neuromyelitis\\_optica\\_134,43/](http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/neuromyelitis_optica_134,43/)
2. [www.mayoclinic.org/diseases-conditions/neuromyelitis-optica/basics/definition](http://www.mayoclinic.org/diseases-conditions/neuromyelitis-optica/basics/definition)
3. [www.guthyjaksonfoundation.org/nmo-faq/](http://www.guthyjaksonfoundation.org/nmo-faq/)
4. Papadopoulos M, Verkman AS. Aquaporin4 and neuromyelitis optica. *Lancet Neuro* 2012; 11: 535–44.
5. [www.my.clevelandclinic.org/Documents/Multiple\\_sclerosis\\_center/Devices.pdf](http://www.my.clevelandclinic.org/Documents/Multiple_sclerosis_center/Devices.pdf)
6. [www.neurology.org/content/66/10/1485](http://www.neurology.org/content/66/10/1485)
7. [www.nih.gov/health/clinicaltrials/basics.htm#4](http://www.nih.gov/health/clinicaltrials/basics.htm#4)
8. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. 2014; *Clinical and Experimental Immunology*, 176: 149–164.

*Research is creating  
new knowledge*

–Neil Armstrong



If you have relapsing Neuromyelitis Optica (NMO) or NMO-Spectrum Disorder (NMO-SD)

You may be eligible to participate in a new research study for the prevention of relapses